CLPT (ClearPoint Neuro) Short-Term Debt: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLPT ClearPoint Neuro Inc CLPT
63 GF Score
Price $15.01
GF Value $14.14
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is ClearPoint Neuro Short-Term Debt?

ClearPoint Neuro CLPT +0.81% 63 Short-Term Debt is $0.00 Mil as of Jun. 2026. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review.

ClearPoint Neuro's Short-Term Debt for the quarter that ended in Jun. 2026 was $0.00 Mil.

ClearPoint Neuro Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

ClearPoint Neuro Short-Term Debt Related Terms

ClearPoint Neuro Short-Term Debt Historical Data

* Premium members only.

The historical data trend for ClearPoint Neuro's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClearPoint Neuro Short-Term Debt Chart

ClearPoint Neuro Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ClearPoint Neuro Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CLPT
63GF Score
ClearPoint Neuro Inc CLPT
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
ClearPoint Neuro (CLPT) has a Short-Term Debt of $0.00 Mil as of Jun. 2026.
Is ClearPoint Neuro's Short-Term Debt too high?
ClearPoint Neuro's current Short-Term Debt is $0.00 Mil. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's Short-Term Debt compare to SI and PACB?
ClearPoint Neuro's Short-Term Debt of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. ClearPoint Neuro's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $15.01 — trading 6.2% above its estimated fair value. The current Short-Term Debt is $0.00 Mil. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current Short-Term Debt is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ClearPoint Neuro (CLPT) Overvalued in 2026?

Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued. The current stock price of $15.01 is trading 6.2% above its estimated GF Value™ of $14.14. GuruFocus considers ClearPoint Neuro to be Fairly Valued.

Key valuation signals for CLPT:

  • Short-Term Debt: $0.00 Mil
  • GF Value™: $14.14 vs. price of $15.01 (6.2% above fair value)
  • GF Score™: 63/100 with 8 warning signs

No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ClearPoint Neuro Business Description

Address 120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score

Get the complete analysis for CLPT

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.01
Price
$14.14
GF Value